Paris, Boston and Sydney, September 18, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today announced that Cellvizio system has been included in the Australian Register of Therapeutic Goods (ARTG). This listing, secured by the Company’s Australian sponsor and exclusive distributor, Endotherapeutics Pty Ltd, enables the commercial launch of Cellvizio in Australia. Mauna Kea has already secured its first two system orders in Australia for use in its new CellTolerance1 indication for food intolerances.
This successful reopening of the Australian market was spearheaded by the commercial team led by Benoit Chardon. The company has also recently strengthened its ties with this experienced team to expand its global reach into other key geographies, including Europe, the Middle East and Latin America, creating a model for new market opportunities.
“We are excited to pave the way for large commercial expansion of the Cellvizio platform in Australia.” said Adam Srejber, CEO of Endotherapeutics Pty Ltd. “We are convinced that this technology can be widely adopted by a wide range of institutions here, and we are already in advanced discussions with a number of interested parties.”
Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies, commented: “We are very proud to open this new market, which is full of opportunity driven by our new indication for food intolerances. In just six months, we have managed to sign an exclusive strategic agreement with a very relevant and active distributor in Australia, and secure the first sales. This is an ideal model that we intend to replicate very quickly in other high-potential territories such as Turkey, Brazil, and the UAE, where we have held regulatory clearances and commercial activity in the past, and where the market potential for Cellvizio and CellTolerance is particularly significant.”
1 See www.cell-tolerance.com for more information.
